The Effects of Liquid IV's Multi-Ingredient Recovery Supplement on Muscle Recovery Following Exercise

NCT07224867 | Not Yet Recruiting

• 1 other identifier: Pro00089373
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to evaluate the efficacy of a multi-ingredient recovery supplement . The research will focus on strength recovery and performance maintenance assessing reductions in soreness and inflammation, as well as muscle repair and damage mitigation. By investigating these key recovery metrics, this study aims to investigate the efficacy of this supplement as a solution for active individuals seeking to optimize post-exercise recovery.

Conditions

Muscle Damage; Strength Recovery; Perceived Recovery; Perceived Muscle Soreness; Physical Performance; Muscle Recovery

Keywords

muscle damage; muscle recovery; strength recovery; physical performance; perceived recovery; perceived muscle soreness

Outcome Measures

Primary Outcomes (5)

• Lower Body Power and Force Generation (Maximal Countermovement Jump (CMJ))

  The force plate platform consists of two force plates (left \& right) containing four force sensors which measure ground reaction force. The sensors are connected to a laptop and analyzed using Mechanography GRFP Research Edition® software (version 4.2-b05.53-RES). Subjects will perform three maximal vertical CMJs on a calibrated force plate. Subjects will be instructed to stand upright on the center of the force plate with feet shoulder-width apart and hands placed on the hips. Subjects will perform a maximal effort vertical jump with proper form and instructed to land with soft knees and remain still after each jump for data capture. A 30sec rest period will be provided between each trial. Data will be used to assess maximum force output (Fmax), rate of force development (RFD), jump height (inches), and maximum power (Pmax). Force curves will be reviewed for each trial, and results averaged. This will quantify full-body mechanical power under standardized, reproducible conditions.

  Taken at baseline testing, 24 hour, 48 hour, and 72 hour.

• Lower-Body Strength (Biodex Dynamometry)

  Participants will complete isometric and isokinetic strength assessments, unilaterally on the dominant leg, of knee extension (ext) and flexion (flx) using a Biodex System 4 Pro dynamometer (Biodex Medical Systems, Shirley, NY). Proper positioning and stabilization will be ensured per manufacturer guidelines. Isometric testing - knee joint will be fixed @60° of flexion. Participants will perform 3 maximal effort ext/flx contractions, each lasting 5sec, with 5sec of rest between efforts. Highest recorded torque value across the 3 trials will be analyzed. Subjects will then complete isokinetic testing consisting of 5 maximal concentric knee ext and flx at an angular velocity of 60°/s. Full range of motion will be established prior to testing. Peak torque and average torque across all 5 repetitions will be recorded for analysis. All torque values will be gravity-corrected by the system software, and same technician will conduct all tests for consistency.

  Tested at baseline, 24 hour, 48 hour, and 72 hour.

• Perceived Recovery Status (PRS) Likert Scale

  The PRS is a composite scale directly proportional to recovery (Laurent, et al. 2011). Hence, the purpose of the scale will be to assess the participant's recovery from the previous exercise session. Subjects will be informed that having no soreness and a high feeling of recovery is a 10, while extreme soreness and low feelings of recovery, leading to limited ability to function, is defined by a range of 0-3, adequate recovery, with some ability to function, is defined by a range of 4-7, and good recovery, with the ability to function normally, is defined by a range of 8-10.

  Taken at baseline testing, 24 hours, 48 hours, and 72 hours timepoints.

• Perceived Body Soreness Likert Scale

  A 7-point likert scale will be used for lower body muscle soreness, after performing 5 air squats. The Likert scale is a validated instrument designed to assess self reported muscle soreness, measured across a 7-point scale. The scale ranges from 0 (no soreness), to 6 (unbearable soreness), and has good validity and reliability (Impellizzeri, F., et al., 2007).

  Taken at baseline testing, 24 hour, 48 hour, and 72 hour timepoints.

• Numeric Pain Rating Scale (NPRS)

  The NPRS is a subjective 11-point numeric pain rating scale, with 0 representing "no pain" and 10 representing "unbearable pain." The Likert scale is a validated instrument designed to assess self reported pain. For this study, the subjects will be asked to assign a number to their average lower extremity joint pain (hip and knee joint pain) (Hawker et al., 2011) at the designated time points.

  NPRS will be taken at baseline, 24 hour, 48 hour and 72 hour time points

Secondary Outcomes (1)

• Body Hydration Status (InBody)

  taken during baseline testing only - before exercise and again at ~10 minutes post treatment

Study Arms (2)

proprietary post workout recovery supplement

EXPERIMENTAL

Liquid I.V. post workout recovery powder mixture

Dietary Supplement: proprietary post workout recovery supplement

Control Treatment

PLACEBO COMPARATOR

inactive/inert placebo mixture

Dietary Supplement: Control placebo

Interventions

proprietary post workout recovery supplement DIETARY_SUPPLEMENT

proprietary post workout recovery supplement

proprietary post workout recovery supplement

Control placebo DIETARY_SUPPLEMENT

inactive/inert placebo mix

Control Treatment

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy males or females aged 18-55 years old.
• Must be recreationally trained or trained/developmental as previously defined (McKay et al., 2021).
• Able to read and write in English.
• Cessation of current use of tart cherry extract, protein powders, essential amino acids/BCAAs, calcium fructoborate, boron, or anabolic agents for a minimum of 1 week prior to, and throughout the duration of the study.
• Willing to maintain regular supplement routine otherwise during the trial, and will not introduce or discontinue a supplement, other than what was previously mentioned.
• Will not participate in any strenuous exercise for a minimum of 1-week prior to exercise performance assessments, as well as during the days of exercise testing. Strenuous exercise as defined for this study includes ½ and full marathons (or more), heavy (i.e.,\>80% 1RM) lifting, and any high intensity, physical activity that could make your muscles sore.
• During the study, you agree not to take any NSAIDs or other anti-inflammatory medications.

You may not qualify if:

• Sedentary
• Highly trained/national level or professional athlete
• Known diagnosis of any cardiovascular, metabolic, musculoskeletal, endocrine, or renal disease/disorder.
• Recent musculoskeletal injury (\<3-months)
• Recent orthopedic surgery (\<12-months)
• History or current malignancy.
• Current respiratory infection (i.e., cold) or high temperature (fever) within the past 4-weeks.
• Previous gastrointestinal surgery within the past 12 months.
• Regular smoker.
• Regular drinker (\>14 drinks per week).
• Those regularly using anti-inflammatory drugs within the last 4-weeks.
• Current use of prescription medications that may influence adaptation to exercise (hormone therapies, peptides, etc.).
• Allergies to study-related materials.
• Any condition that impairs their ability to complete the required exercises.
• Female subjects must not be pregnant or lactating.

Sponsors & Collaborators

• Applied Science & Performance Institute: lead

Study Sites (1)

Applied Science & Performance Institute

Tampa, Florida, 33634, United States

Location

Related Publications (6)

• Skurvydas A, Brazaitis M, Venckunas T, Kamandulis S. Predictive value of strength loss as an indicator of muscle damage across multiple drop jumps. Appl Physiol Nutr Metab. 2011 Jun;36(3):353-60. doi: 10.1139/h11-023. Epub 2011 May 16.

  PMID: 21574783 BACKGROUND

• Shimomura Y, Yamamoto Y, Bajotto G, Sato J, Murakami T, Shimomura N, Kobayashi H, Mawatari K. Nutraceutical effects of branched-chain amino acids on skeletal muscle. J Nutr. 2006 Feb;136(2):529S-532S. doi: 10.1093/jn/136.2.529S.

  PMID: 16424141 BACKGROUND

• Connolly DA, McHugh MP, Padilla-Zakour OI, Carlson L, Sayers SP. Efficacy of a tart cherry juice blend in preventing the symptoms of muscle damage. Br J Sports Med. 2006 Aug;40(8):679-83; discussion 683. doi: 10.1136/bjsm.2005.025429. Epub 2006 Jun 21.

  PMID: 16790484 BACKGROUND

• Blomstrand E, Eliasson J, Karlsson HK, Kohnke R. Branched-chain amino acids activate key enzymes in protein synthesis after physical exercise. J Nutr. 2006 Jan;136(1 Suppl):269S-73S. doi: 10.1093/jn/136.1.269S.

  PMID: 16365096 BACKGROUND

• Impellizzeri FM, Maffiuletti NA. Convergent evidence for construct validity of a 7-point likert scale of lower limb muscle soreness. Clin J Sport Med. 2007 Nov;17(6):494-6. doi: 10.1097/JSM.0b013e31815aed57.

  PMID: 17993794 BACKGROUND

• Laurent CM, Green JM, Bishop PA, Sjokvist J, Schumacker RE, Richardson MT, Curtner-Smith M. A practical approach to monitoring recovery: development of a perceived recovery status scale. J Strength Cond Res. 2011 Mar;25(3):620-8. doi: 10.1519/JSC.0b013e3181c69ec6.

  PMID: 20581704 BACKGROUND

Study Officials

• Eric Sikorski, PhD

  Applied Science and Performance Institute

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Eric Sikorski, PhD

CONTACT

8138678888; esikorski@theaspi.com

Gabe Wilson, PhD

CONTACT

8138678888; gwilson@theaspi.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: randomized, double-blind, crossover study

Study Record Dates

• First Submitted: November 3, 2025
• First Posted: November 5, 2025
• Study Start: May 1, 2026
• Primary Completion (Estimated): October 1, 2026
• Study Completion (Estimated): October 1, 2026
• Last Updated: April 9, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)